Clinical impact of Ocrelizumab extended interval dosing during the COVID-19 pandemic and associations with CD19+ B-cell repopulation
| Autor: | Roby J Abraham, Omar Salim, Adnan Al-Araji, Seema Kalra, Nitin Kumar Sahi, Syed Muhammad Ali Abidi |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Coronavirus disease 2019 (COVID-19)
Antibodies Monoclonal Humanized Article CD19 Multiple sclerosis Pandemic medicine Humans Ocrelizumab Pandemics B cell biology SARS-CoV-2 business.industry COVID-19 General Medicine medicine.disease Virology Extended interval dosing medicine.anatomical_structure Neurology biology.protein Repopulation Neurology (clinical) business Extended dosing medicine.drug |
| Zdroj: | Multiple Sclerosis and Related Disorders |
| ISSN: | 2211-0348 |
| DOI: | 10.1016/j.msard.2021.103287 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect